{
  "docId": "019de073-7cac-75f7-8c4d-c1df42c29745",
  "docSlug": "674201d8cef93b1820f78aa5772cd90f",
  "documentTitle": "ATAI | Investor Presentation Deck | 36 slides",
  "authorId": "atai",
  "authorName": "atai Life Sciences",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 36,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a split-layout with a dark sidebar for summary metrics and a white main area for clinical data visualization.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-7cac-75f7-8c4d-c1df42c29745/14",
  "deckHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745",
  "deckJsonHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745.json",
  "deckAnchorHref": "/decks/019de073-7cac-75f7-8c4d-c1df42c29745#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.15,
        "x": 0.7,
        "y": 0.55
      },
      "kind": "callout",
      "text": "CADSS score below 4 considered 'normal'",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "495fa2ce-5423-4030-807d-85e24adb33e1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.25,
        "x": 0.7,
        "y": 0.34
      },
      "kind": "callout",
      "text": "Comparable S-Ketamine dose typically results in a CADSS score of 15",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6405f9ad-6930-4265-9be2-69021ca561d1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.3,
        "x": 0.36,
        "y": 0.34
      },
      "kind": "chart",
      "text": "MADRS score over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5d50131c-1441-4ea5-a906-51f63abdf40f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.4,
        "w": 0.28,
        "x": 0.68,
        "y": 0.34
      },
      "kind": "chart",
      "text": "CADSS score over time",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ca009c1f-dcf2-435b-b833-d804f6a2257b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.36,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "Note: MADRS = Montgomery-Asberg Depression Rate Scale, CADSS = Clinician-administered dissociative states scale, IV = Intravenous, PBO = Placebo. (1) Ownership... (2) Third party study... (3) Singh et al...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c7ec507b-3bc6-4bd4-80cd-881dd2ae608b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.65,
        "w": 0.32,
        "x": 0.03,
        "y": 0.17
      },
      "kind": "list",
      "text": "Ownership: 58.9% | Product: Subcutaneous R-ketamine | Pharmacology: Glutamatergic modulator | Features: Rapid-acting, nonpsychedelic | Indications: TRD, SUD | Status: Phase 2a initiated | IP: Issued methods | Highlight: Rapid/sustained MADRS decrease",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dd7ff14f-3331-445d-a5a3-91d5ac226b09",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.15,
        "x": 0.03,
        "y": 0.08
      },
      "kind": "title",
      "text": "SUMMARY",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c2bce13d-21f8-4adc-81b4-bc92c0c956be",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Executive summary",
      "slug": "executive-summary",
      "agent": null,
      "layer": "slide",
      "matchId": "a45fa40d-deda-4032-a204-c5842e371b22",
      "evidence": "title/headline: We aim to develop PCN-101 as a rapid acting antidepressant with potential for at-home use",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}